Senti Biosciences (NASDAQ:SNTI – Get Free Report) issued its earnings results on Monday. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.16), reports.
Senti Biosciences Stock Down 2.8%
Senti Biosciences stock traded down $0.00 during mid-day trading on Wednesday, reaching $0.09. 196,277 shares of the company’s stock were exchanged, compared to its average volume of 1,182,304. The business’s fifty day simple moving average is $0.25 and its 200 day simple moving average is $0.67. The firm has a market capitalization of $2.94 million, a PE ratio of -0.05 and a beta of 2.31. Senti Biosciences has a one year low of $0.09 and a one year high of $2.88.
Senti Biosciences’s stock is scheduled to reverse split on Thursday, November 19th. The 1-33 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, November 18th.
Analyst Ratings Changes
Read Our Latest Report on SNTI
Senti Biosciences Company Profile
Senti Biosciences is a biotechnology company focused on developing cell and gene therapies using synthetic biology. Its platform uses engineered gene circuits designed to help therapeutic cells recognize disease-related signals and respond in a controlled way. The company has worked on engineered immune-cell treatments, including allogeneic CAR-NK candidates. Its pipeline has included programs aimed at blood cancers and solid tumors, such as SENTI-202 and SENTI-301A. Founded in 2016 and based in South San Francisco, California, Senti Biosciences has concentrated its research and development activities in the United States.
Read More
- Five stocks we like better than Senti Biosciences
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
